Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
about
S100A9 interaction with TLR4 promotes tumor growthTasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironmentA Perspective of Immunotherapy for Prostate CancerTasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospectsMechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancerCommon interactions between S100A4 and S100A9 defined by a novel chemical probeBone-targeting agents in prostate cancer.Emerging treatment options for patients with castration-resistant prostate cancer.The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer.Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancerThe biology of castration-resistant prostate cancerTasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsThe anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growthCurrent and emerging therapies for bone metastatic castration-resistant prostate cancer.Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.Novel therapies for the treatment of advanced prostate cancer.New strategies for medical management of castration-resistant prostate cancer.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).Antiangiogenic and anticancer molecules in cartilage.Current and emerging treatments in the management of castration-resistant prostate cancer.Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.A review of tasquinimod in the treatment of advanced prostate cancer.Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.Mechanisms of action of tasquinimod on the tumour microenvironment.Castration-resistant prostate cancer: latest evidence and therapeutic implications.Selective class IIa HDAC inhibitors: myth or reality.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.Immunotherapy for prostate cancer: False promises or true hope?Tasquinimod: a novel drug in advanced prostate cancer.Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.S100A9 and tumor growthDNA vaccines for prostate cancer.Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo.A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
P2860
Q21134707-226D372B-5667-439D-8C2F-4A151C037819Q24618224-6905406D-34E6-473B-8E42-724FC0583A7EQ26741277-32ED2C72-FE1E-4BD0-9C81-F4FAC2DE21C7Q26770428-C2F66B2C-FF53-46CD-9AC1-BCFABF0A3F4CQ27024795-99B4B75E-413F-44D7-90CD-D24870CE5621Q28487759-2022F907-3DF8-4E8F-ADAC-D85535674787Q33864723-0A39A8EE-ED40-4A66-84D0-EF5BF72B800EQ33958519-183EAC0B-3C00-40CA-A86C-E0A66CFAB37BQ34013840-54843D18-AC87-4F18-B20C-D84DC066ACF8Q34250496-F047DB42-12BB-4C28-BF01-DE3F4A806F8BQ34608976-D86DBF82-A6AD-4B41-A17C-9A24C8CFB2FAQ35039889-40718EE8-0F58-484B-AABF-FE90EB97AAA7Q35071167-A20A6925-A99A-4151-880B-C9DD9B97A696Q36072831-3FAAA296-4FB0-41B3-8EB1-74BF5E6714D0Q36358303-F3B9DB35-C37B-4851-9C6D-CE9CD705CA3DQ36370409-02B9D481-C679-4E69-ADBD-B20B5622713AQ36665708-576B31C4-8F9B-4A4D-99B4-28A83F8C6D31Q37876123-CEED6735-027E-4188-BA06-29D690A316B4Q37950459-3706ACBD-BC62-42ED-96BA-DD67524179E2Q38007565-E192FED6-2A92-4C57-A050-E872E2143CC7Q38030595-214BC312-06B5-46BB-941F-402BC80FD85DQ38075446-E8F211D6-845B-4D9A-BD9F-01522C6CBF22Q38105544-319AC49F-4470-44AA-988C-56660DE887B8Q38113142-931568B1-C9EE-418B-81B6-699481335511Q38155757-BC355F0B-D970-417D-8757-D1FFC1A25E8AQ38233358-AEF2AEC5-2CD2-43DC-988F-3BF2B8A0F3D4Q38246144-6503F543-D8E4-42EB-9F11-B07D33D06CF7Q38723404-F387A4D2-CF3C-46E9-9260-7C86968BE2D0Q38812152-8575D741-0304-4FD7-BB03-49637917A24FQ38959297-35B5A1A8-78AC-48F1-A79A-F845065D251AQ38959645-F7FE9127-E4D7-41BF-AC3E-1A229609D1EBQ39360781-82835D3E-3F4F-474A-82D1-D2C4072000CAQ40468733-C6DC7668-088E-489E-A41B-88DDDE2EE630Q41836745-95F3A370-E4C9-4238-A66B-CEA2AC0506BEQ42403250-BC63A7B6-387B-4431-BA3B-B44133D5BD85Q51142505-F582FC04-BE00-46A2-BBD0-309647E1DE26Q52894128-7E5B91A6-B790-4210-BF04-02806A74F8B3Q54572103-58800F68-82D0-40D6-B33F-E072C15EBB98
P2860
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@ast
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@en
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@en-gb
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@nl
type
label
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@ast
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@en
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@en-gb
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@nl
prefLabel
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@ast
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@en
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@en-gb
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@nl
P2093
P2860
P3181
P356
P1433
P1476
Tasquinimod (ABR-215050), a qu ...... din-1 in human prostate tumors
@en
P2093
Anders Björk
Anders Olsson
John T Isaacs
Tomas Leanderson
P2860
P2888
P3181
P356
10.1186/1476-4598-9-107
P407
P577
2010-01-01T00:00:00Z
P5875
P6179
1010978668